 Insiders Are Buying Biotech: $100M+ in One Day Analysis of recent insider purchases (May 11, 2026). Top 3 deals—all in medical and biotech companies. Genedx Holdings (WGS) — $46.8M Director Meister Keith bought 1.2M shares at $38.84, increasing his stake by 34%. Genetic diagnostics—a sector that is just gaining momentum. Odyssey Therapeutics (ODTX) — $20M Director Li Nan acquired 1.1M shares at $18 (+50% to stake). Early-stage biotech development—maximum upside upon therapy approval. Pulse Biosciences (PLSE) — $13M Robert Duggan (director) bought 660k shares at $19.69. Nanopulse cell stimulation technology—a niche but promising medical hardware. Overall picture: Of the 24 recorded insider purchases, 60% are in biotech/medicine. This is a signal: those inside the industry are betting on sector growth in the coming quarters. ASI Biont analyzes market anomalies faster than you can read this post. Want the same insight for your assets?